3 Million+ Unique Research Compounds, Real-time Pricing & Availability
Sign in to enjoy up to 20% OFF or Sign Up
  • Product Search
     
[email protected]
  • Product Search
     
Chemistry
Bioactive Molecules
Screening Libraries
Natural Products
Material Science
ADCs
PEG
Antibodies
Consumables
+1 800-931-7508 [email protected]
Sign in to enjoy up to 20% OFF

[CAS NO. 50-18-0]  Cyclophosphamide

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [50-18-0]

Store
Catalog
HY-17420
Brand
MCE
CAS
50-18-0

DESCRIPTION [50-18-0]

Overview

MDL-
Molecular Weight261.09
Molecular FormulaC7H15Cl2N2O2P
SMILESClCCN(CCCl)P1(OCCCN1)=O

For research use only. We do not sell to patients.

11 Publications Citing Use of MCE


Summary

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic activity, a immunosuppressant.


IC50 & Target

DNA Alkylator [1]


In Vitro

Cyclophosphamide induces outer membrane blebbing, leads to DNA fragmentation, as revealed by TUNEL staining of free 3'-OH DNA ends, and induces cleavage of the caspase 3 and caspase 7 substrate PARP in 9L/P450 cells. Bcl-2 expression fully blocks the activation of both initiator caspases as well as the effector caspase 3 in cells treated with activated Cyclophosphamide. Bcl-2 inhibits the cytotoxic effects but not the cytostatic effects of activated Cyclophosphamide [1] . Cyclophosphamide inhibits the AChE reversibly with an IC 50 of 511 μM [2] . Carbon tetrachloride does not affect the direct cytotoxicity of cyclophosphamide or 4-hydroxycyclophosphamide to cells in culture [3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

Cyclophosphamide (injected i.p.;2mg/mouse in 0.1 mL PBS, in C3H mice bearing SW1 tumors) increases the percentage of cells that stained for CD3, CD4 or CD8 in both spleens and tumors [4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Six to eight-week old female C3H/HeN mice bearing SW1 tumors [4]
Dosage: 2 mg/mouse
Administration: Injected i.p.; 2mg/mouse in 0.1 mL PBS; 4 days
Result: Increased the percentage of cells that stained for CD3, CD4 or CD8 in both spleens and tumors.

Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT03107988 New Approaches to Neuroblastoma Therapy Consortium|Pfizer|University of Southern California|Solving Kids´ Cancer US+EU|Children´s Neuroblastoma Cancer Foundation|The Band of Parents|The Evan Foundation|Wade´s Army|Ronan Thompson Foundation|The Catherine Elizabeth Blair Memorial Foundation|Cookies for Kids´ Cancer
Neuroblastoma
September 5, 2017 Phase 1
NCT02999854 Kiadis Pharma
Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome
November 29, 2017 Phase 3
NCT01962636 Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia (AML)|Acute Lymphocytic Leukemia (ALL)|Chronic Myelogenous Leukemia|Plasma Cell Leukemia|Myelofibrosis|Myelodysplasia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone B-Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Lymphoblastic Lymphoma|Burkitt´s Lymphoma|Non-Hodgkin Lymphoma|Multiple Myeloma
December 2016 Not Applicable

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, protect from light

* The compound is unstable in solutions, freshly prepared is recommended.


Solvent & Solubility

In Vitro:

DMSO : ≥ 38 mg/mL ( 145.54 mM )

H 2 O : 33.33 mg/mL ( 127.66 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.8301 mL 19.1505 mL 38.3010 mL
5 mM 0.7660 mL 3.8301 mL 7.6602 mL
10 mM 0.3830 mL 1.9150 mL 3.8301 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: PBS

    Solubility: 25 mg/mL (95.75 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

  • 2.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (9.58 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (9.58 mM); Clear solution

  • 4.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (9.58 mM); Clear solution

* All of the co-solvents are available by MCE.


Synonyms

2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide
B 518
NSC 26271
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
N,N-Bis(2-chloroethyl)-N′,O-propylenephosphoric acid ester diamide
N,N-Bis(β-chloroethyl)-N′,O-trimethylenephosphoric acid ester diamide
Cyclophosphamid
Cyclophosphamide
Cyclophosphan
Cyclophosphane
Cytoxan
Endoxan
Genoxal
Clafen
Cytophosphan
Claphene
Asta B 518
2-[Bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide
Procytox
Sendoxan
(±)-Cyclophosphamide
(RS)-Cyclophosphamide
Cyclostin
Cycloblastin
Neosar
Neosar (antineoplastic)
Endoxanal
CP
Senduxan
Zyklophosphamid
NCI C04900
Endoxan R
Endoxan-Asta
Endoxana
Mitoxan
Endoxane
Enduxan
CB 4564
SK 20501
CPA
CY
Hexadrin
Cyclophosphamidum
CTX
Semdoxan
Revimmune
Ledoxan
Cytophosphane
Eldamide
Neophos
Cyphos
Cydoxan
Cycrame
Oncomide
Cyclocel
Cycloxan

Information
Shipping
Privacy notice
Terms of Service
About us
Contact us
FAQs
Customer service
Search
Custom Synthesis
My account
My account
Orders
Addresses
Shopping cart
Suppliers
Supplier Sign In
Become a Supplier
Pay
Follow us
Powered by Arctom Copyright © 2026 Arctom. All rights reserved.